Structurally-defined αMHC-II nanobody-drug conjugates: Therapeutic and imaging platforms for B-cell lymphoma

Fang, Tao; Duarte, Joao N.; Ling, Jingjing; Li, Zeyang; Guzman, Jonathan S.; Ploegh, Hidde L.

doi:10.1002/anie.201509432

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Structurally-defined αMHC-II nanobody-drug conjugates: Therapeutic and imaging platforms for B-cell lymphoma

Published Date:

Jan 14 2016

Publisher's site:

http://dx.doi.org/10.1002/anie.201509432 New Site Icon

Source:

Angew Chem Int Ed Engl. 55(7):2416-2420.

[PDF-1.06 MB]

Details:

Personal Authors:

Fang, Tao ; Duarte, Joao N. ; Ling, Jingjing ; Li, Zeyang ; Guzman, Jonathan S. ; ... More ▼

Keywords:

[+]

Pubmed ID:

26840214

Pubmed Central ID:

PMC4820396

Description:

Antibody-drug conjugates (ADCs) of defined structure hold great promise for cancer therapies, but further advances are constrained by the complex structures of full-sized antibodies. Camelid-derived single-domain antibody fragments (VHHs or nanobodies) offer a possible solution to this challenge by providing expedited target screening and validation through switching between imaging and therapeutic activities. We used a nanobody (VHH7) specific for murine MHC-II and rendered "sortase-ready" for the introduction of oligoglycine-modified cytotoxic payloads or NIR fluorophores. The VHH7 conjugates outcompeted commercial monoclonal antibodies (mAbs) for internalization and exhibited high specificity and cytotoxicity against A20 murine B-cell lymphoma. Non-invasive NIR imaging with a VHH7-fluorophore conjugate showed rapid tumor targeting on both localized and metastatic lymphoma models. Subsequent treatment with the nanobody-drug conjugate efficiently controlled tumor growth and metastasis without obvious systemic toxicity.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

DP1 GM106409/GM/NIGMS NIH HHS/United States
R01 AI087879/AI/NIAID NIH HHS/United States
DP1 GM106409/DP/NCCDPHP CDC HHS/United States
R01AI087879/AI/NIAID NIH HHS/United States

Supporting Files:

	nihms768894f4.gif	image/gif
	nihms768894f4.jpg	image/jpeg
	NIHMS768894-supplement-Supporting_Information.pdf	application/pdf
	nihms768894.nxml	application/octet-stream
	nihms768894f1.gif	image/gif
	nihms768894f1.jpg	image/jpeg
	nihms768894f2.gif	image/gif
	nihms768894f2.jpg	image/jpeg
	nihms768894f3.gif	image/gif
	nihms768894f3.jpg	image/jpeg

No Related Documents.

You May Also Like:

VHH antibodies: Emerging reagents for the analysis of environmental chemicals

Personal Author:

Bever, Candace S.; Dong, Jie-Xian; Vasylieva, Natalia; Barnych, Bogdan; Cui, Yongliang; Xu, Zhen-Lin; Hammock, Bruce D.; Gee, Shirley J.;

Published:

May 21 2016

Source:

Anal Bioanal Chem. 408(22):5985-6002.

Description:

A VHH antibody (or nanobody) is the antigen binding fragment of heavy chain only antibodies. Discovered nearly 25 years ago, they have been investigated for their use in clinical therapeutics and immunodiagnostics, and more recently for environmenta...

File Type:

[PDF - 1.27 MB]
CD30 is a potential therapeutic target in malignant mesothelioma

Personal Author:

Dabir, Snehal; Kresak, Adam; Yang, Michael; Fu, Pingfu; Wildey, Gary; Dowlati, Afshin;

Published:

Jan 14 2015

Source:

Mol Cancer Ther. 14(3):740-746.

Description:

CD30 is a cytokine receptor belonging to the TNF superfamily (TNFRSF8) that acts as a regulator of apoptosis. The presence of CD30 antigen is important in the diagnosis of Hodgkin disease and anaplastic large cell lymphoma. There have been sporadic r...

File Type:

[PDF - 761.47 KB]
Peroxidase-mediated Biodegradation of Carbon Nanotubes in vitro and in vivo

Personal Author:

Kotchey, Gregg P.; Zhao, Yong; Kagan, Valerian E.; Star, Alexander;

Published:

Jul 12 2013

Source:

Adv Drug Deliv Rev. 2013; 65(15):1921-1932.

Description:

As a result of their unique electronic, optical, and mechanical properties, carbon nanotubes (CNTs) have been implemented in therapeutic and imaging applications. In an idealized situation, CNTs would be disposed of after they transport their therano...

File Type:

[PDF - 1.12 MB]
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma

Personal Author:

Landgren, Ola; Rajkumar, S. Vincent;

Published:

Nov 15 2016

Source:

Clin Cancer Res. 22(22):5428-5433.

Description:

Over the past few years, the management of multiple myeloma has changed. We have new guidelines regarding how to set the diagnosis, when to initiate therapy, and how to monitor treatment response. In 2014, the updated International Myeloma Working Gr...

File Type:

[PDF - 522.10 KB]
Conference Highlights of the 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses, 26–30 June 2013, Montreal, Canada

Personal Author:

Barbeau, Benoit; Hiscott, John; Bazarbachi, Ali; Carvalho, Edgar; Jones, Kathryn; Martin, Fabiola; Matsuoka, Masao; Murphy, Edward L; Ratner, Lee; Switzer, William M; Watanabe, Toshiki;

Published:

Feb 24 2014

Source:

Retrovirology. 2014; 11:19.

Description:

The 16th International Conference on Human Retrovirology: HTLV and Related Retroviruses was held in Montreal, Québec from June 26th to June 30th, 2013 and was therefore hosted by a Canadian city for the first time. The major topic of the meeting was...

File Type:

[PDF - 409.32 KB]